Renewals Submissions

Freyr offers comprehensive Marketing Authorization renewal services, ensuring continuous product validity in the EU market. Our expertise covers timely tracking, document assessment, and submission management for efficient license renewals across European Health Authorities.

Renewals Submissions - Overview

In accordance with Article 14(1-3) of Regulation (EC) No 726/2004, any Marketing Authorization (MA), except those granted under exceptional circumstances, is valid until five (5) years from the date of approval. To remain valid and/or to extend the validity, the renewal of the marketing authorization is required before the date of the expiry. 

After the renewal, the validity of the MAA shall be for a fixed or indefinite period. Once the MAA license is renewed, it is valid for a lifetime unless the competent member authority of the EU member state decides to have one more renewal based on pharmacovigilance and to process with an additional 5-year renewal.
Hence, Marketing Authorization Holders (MAH) need to maintain the validity of the application to continue the distribution in the EU region. At Freyr, our Regulatory experts can assist the MAHs by handling and filing the license renewal application with a very efficient tracking system to manage the timely submission of renewals to HAs.

Renewals Submissions - Expertise

  • Tracking of MAA license renewal application due date
  • Send the renewal initiation documents request to the manufacturer
  • Regulatory assessment of the supporting documents for renewal application submission
  • Request for additional documents/justification
  • Compilation and review of renewal dossier
  • Finalization of renewal dossier and submission to Health Authority before the due date of the license renewal application
Renewals Submissions

Celebrating Customers Success

 

Medicinal Products

Regulatory Affairs

India

Thank you for the timely support over the weekend, which allowed us to resubmit quickly after being notified. This continuously demonstrates Freyr's commitment towards our company’s milestones.

Director - Global Regulatory Affairs – Operations

India-based, Global Top Generic Pharma Company

 

Medicinal Products

Publishing

UK

I am sure you have heard by now that we have received our first-ever approval from the FDA for our Brands division. This is a major milestone for us as well as for my team here in Reg Ops. I would be remiss if I didn’t point out that we would not have been able to do this without the help of your dedicated team. From the original filing, then the following year of responses, all helped get us to final approval.

Thank you Freyr team for a job well done!

Sr. Director, Head of Regulatory Operations

Ireland-based, Global Specialty Pharmaceutical Company

 

Medicinal Products

Regulatory Affairs

USA

Please relate to the team the excellent job they have done on the IND reactivation. Specifically, the high-quality module 3, written by Freyr. It was very comprehensive, very few revisions were required, and we had no questions from Health Canada or FDA. No CMC questions: that was a first for me. So very responsive to my many requests, which I am sure can be frustrating but always helpful while producing excellent work.

Thank you for always being available and responding quickly and comprehensively to all my requests.

What a great team you have, Freyr.

Lynne McGrath

Regulatory Consultant

 

Medicinal Products

Regulatory Affairs

USA

Congratulations!!! ​

Thanks for your great support for a successful ANDA filing, especially to the publishing team. Heartfully appreciate their last hours of hard work.

Assistant Manager​

US-based, Leading, Complex Generic Pharmaceutical Products Company​

 

Medicinal Products

Regulatory Affairs

USA

Thank you all for the great support!​

CEO

US-based, Leading Innovative Pharmaceuticals Company​

 

Medicinal Products

Regulatory Affairs

USA

The ANDA receipt has been received! Thank you very much for your hard work, patience, and support for our work over the last couple of months. We are delighted that we were able to meet the timeline and hit an important corporate goal of our young company. ​

Thank you again, and we look forward to working with your team on the next project!

Senior Director of Business and Product Development​

US-based, Leading Innovator Pharmaceuticals Company​